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Abstract
Background: Expression levels of mRNA and protein by cell types exhibit a range of correlations
for different genes. In this study, we compared levels of mRNA abundance for several cluster
designation (CD) genes determined by gene arrays using magnetic sorted and laser-capture
microdissected human prostate cells with levels of expression of the respective CD proteins
determined by immunohistochemical staining in the major cell types of the prostate – basal
epithelial, luminal epithelial, stromal fibromuscular, and endothelial – and for prostate precursor/
stem cells and prostate carcinoma cells. Immunohistochemical stains of prostate tissues from more
than 50 patients were scored for informative CD antigen expression and compared with cell-type
specific transcriptomes.
Results: Concordance between gene and protein expression findings based on 'present' vs. 'absent'
calls ranged from 46 to 68%. Correlation of expression levels was poor to moderate (Pearson
correlations ranged from 0 to 0.63). Divergence between the two data types was most frequently
seen for genes whose array signals exceeded background (> 50) but lacked immunoreactivity by
immunostaining. This could be due to multiple factors, e.g. low levels of protein expression,
technological sensitivities, sample processing, probe set definition or anatomical origin of tissue and
actual biological differences between transcript and protein abundance.
Conclusion: Agreement between these two very different methodologies has great implications
for their respective use in both molecular studies and clinical trials employing molecular
biomarkers.
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Background
Immunostaining and microarray analysis are techniques
frequently used to characterize tissue phenotypes. Immu-
nohistochemistry (IHC) is a method of assessing protein
levels of gene expression that is based on the ability of
antibodies to bind proteins expressed by cells in sections
of frozen or formalin-fixed, paraffin-embedded tissues.
IHC enables one to detect and localize a specific antigen
to specific cell types. Gene arrays determine expression
levels for thousands of genes simultaneously by detecting
sequence segments or partial segments of mRNA in a sam-
ple. To fully understand the underlying mechanisms of
biological processes, it is essential to determine whether
observed changes in mRNA can also be seen in the trans-
lated protein, and to pinpoint what cell types are exhibit-
ing these changes. Gene array analysis and
immunostaining are powerful tools for determining gene
and protein expression patterns in health and diseases.
Establishing the extent of agreement between semi-quan-
titative immunostaining data and gene array data
obtained from sorted cell populations and tissue speci-
mens is important to account for possible discrepancies
between these two very different methods.
Determining a direct relationship between protein and
mRNA levels can be problematic, and previous efforts to
find correlations have found variable success. A study
comparing yeast proteomic and transcriptomic data
showed that correlation was insufficient to predict protein
expression levels from mRNA except for the most abun-
dant proteins, suggesting that protein abundance may be
a factor that influences the correlation between mRNA
and protein [1]. However, a relationship between mRNA/
protein correlation coefficient and protein abundance was
not observed in a study of human lung adenocarcinomas
[2] or in a study of MMP-2, MMP-9 and TIMP-1 in human
prostate cancers [3]. For some genes, such as HER2/neu,
expression levels assayed by RT-PCR, IHC and fluores-
cence in situ hybridization (FISH) in breast tumors show
highly significant correlation among these techniques [4].
However, studies evaluating the overall concordance
between protein and RNA expression levels have found
wide variability. For example, transcript and protein con-
cordance in the LNCaP prostate cancer cell line has been
reported to vary from 32% [5] to 83.5% [6]. Highly signif-
icant correlations in mRNA changes and protein expres-
sion levels were found by Orntoft et al. in human
carcinomas [7]. Studies such as these suggest that external
factors as well as actual biological differences between
mRNA and protein abundance might affect the relation-
ships between the two data types.
The assessment of CD24 as a potential prostate cancer
biomarker through RNA expression profiling and IHC
analysis in previous studies further illustrates the difficul-
ties in directly comparing gene and protein expression lev-
els. Normalized CD24 transcript levels showed an average
2.69-fold increase in prostate cancer as determined by
qPCR [8] and an increase in staining intensity as deter-
mined by IHC [9]. Two reports by Kristiansen et al. found
differential CD24 gene expression in 38.5% of tumor
cases as determined by Affymetrix GeneChip analysis [10]
and 48% as examined by IHC [11]. It is unclear if the 10%
disparity between these studies has biological signifi-
cance, or if a component of the measured difference is due
to technical attributes of the assays. Although, based on
these studies, CD24 could potentially be an important
prognostic prostate cancer tissue marker, the relationship
between mRNA levels and resulting protein expression
remains unclear.
Our laboratory has previously characterized benign and
neoplastic prostate tissues by CD phenotype [9,12] and
isolated the constituent cell types with magnetic cell sort-
ing (MACS) for gene expression analysis [13]. In the
present study, we compared the expression levels of a
panel of 58 informative CD antigens in prostate tissue
scored by immunostaining with expression levels of the
respective mRNA by microarray-based quantitation of
MACS-sorted and laser capture microdissected (LCM) cell
populations. Our objective was to characterize the rela-
tionship between protein and mRNA levels measured by
these two techniques.
Results
Immunolocalization and transcriptome data summary
To determine correlations between disparate methods of
assessing gene expression levels, we selected a cohort of
CD antigens as a reference gene set and compared tran-
script abundance measurements acquired by microarray
hybridization with protein abundance measurements
determined by immunohistochemistry in specific cell
types found in the human prostate gland. The microarray
and immunostaining results for each cell type are summa-
rized in Figure 1. All annotations are deposited in a public
database [14]. The sample data conform to the Minimum
Information Specification For In Situ Hybridization and
Immunohistochemistry Experiments (MISFISHIE) stand-
ards [15], and describe the tissue, distribution of reaction
product in the tissue, localization pattern within cell
types, and provide an assessment of the level of protein
expression based on the immunostaining data. Our initial
criteria for assessing expression centered on using 'present'
vs. 'absent' call for both Affymetrix and Agilent array anal-
yses. Based on this qualification, CD antigen expression
for MACS-sorted cell populations agreed with the follow-
ing frequency to IHC data by cell type: endothelial = 55%,
luminal = 64%, stromal = 46%, basal epithelial = 63%,
stem = 64%, cancer = 68%. CD antigen expression for
LCM cells analyzed by Affymetrix array agreed 39% forBMC Genomics 2008, 9:246 http://www.biomedcentral.com/1471-2164/9/246
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stromal cells with IHC data, and analyzed by Agilent array
agreed 25% for stromal cells and 36% for luminal cells.
We next sought to establish a more quantitative relation-
ship between CD immunoreactivity of prostate cells and
corresponding gene expression data (Figure 2). For exam-
CD expression summary Figure 1
CD expression summary. CD expression levels of prostate tissue as scored by immunostaining (IHC) and gene array 
(mRNA) for each constituent cell type. Overall concordance between IHC and MACS-sorted cell gene array ranged from 46 
to 67% and was determined as the percentage of agreement for each cell type based on 'present' or 'absent' call for the total 
number of IHC and mRNA determinations. Concordance between IHC and LCM Affymetrix gene array for stromal cells was 
39%. Concordance between IHC and LCM Agilent gene array was 25% for stromal cells and 36% for luminal cells.
Cell type: Endothelial Luminal Stromal Basal Progenitor 
Cancer (Gleason Pattern 3 
+ 3 = 6 tumor)
CD
HUGO 
Gene 
Symbol IHC
Affymetrix 
mRNA IHC
Affymetrix 
mRNA
Agilent LCM 
mRNA IHC
Affymetrix 
mRNA
Affymetrix 
LCM mRNA
Agilent LCM 
mRNA IHC
Affymetrix 
mRNA IHC
Affymetrix 
mRNA IHC
Affymetrix 
mRNA
CD1a CD1A 0.00 35 0.00 32 31 0.10 28 171 133 0.00 29 0.00 24 22
CD6 CD6 0.00 32 0.04 31 58 0.00 26 92 33 0.00 27 0.00 26 0.35 26
CD9 CD9 0.00 6161 1.00 7062 60150 0.22 2714 467 11577 1.00 6899 1.00 8802 0.63 7261
CD10 MME 0.00 55 0.61 1416 549 0.01 223 687 32 0.00 562 0.00 40 0.17 84
CD13 ANPEP 0.23 221 0.89 361 12623 0.23 97 32 269 0.24 79 0.24 103 0.19 25
CD24 CD24 0.00 219 0.19 1254 1162 0.01 405 142 212 0.00 548 0.00 120 0.96 1886
CD26 DPP4 0.58 40 0.75 759 31647 0.00 48 147 275 0.00 124 0.00 29 0.80 570
CD29 ITGB1 0.05 9 0.00 9 14926 0.84 9 2033 18957 0.00 10 0.00 10 0.33 9
CD30 TNFRSF8 0.00 25 0.05 24 25 0.03 23 217 40 0.00 23 0.00 26 0.00 24
CD32 FCGR2B 0.00 38 0.00 20 315 0.00 37 46 255 0.07 20 0.07 36 0.00 7
CD38 CD38 0.05 143 0.62 670 2652 0.00 101 86 40 0.29 163 0.29 51 0.56 388
CD40 CD40 0.00 402 0.00 182 117 0.00 170 177 84 0.18 157 0.18 398 0.91 1017
CD41 ITGA2B 0.00 27 0.00 29 274 0.00 28 24 139 0.00 28 0.00 29 0.00 30
CD43 SPN 0.00 37 0.00 39 3034 0.00 35 183 2233 0.00 36 0.00 39 0.00 36
CD44 CD44 0.00 1009 0.00 606 5483 0.00 780 224 2206 0.30 701 0.30 565 0.19 377
CD45 PTPRC 0.00 310 0.00 219 231 0.00 227 363 159 0.00 23 0.00 100 95
CD46 CD46 0.00 318 477 3650 0.00 222 399 992 398 372 0.66 391
CD47 CD47 0.00 279 0.08 814 13373 0.91 376 1826 2484 0.63 462 0.63 282 0.00 711
CD49a ITGA1 0.00 889 0.00 320 48 0.84 2360 1331 1590 0.00 303 0.00 1038 0.00 205
CD49b ITGA2 0.30 1533 0.02 2115 817 0.00 610 142 166 0.91 2327 0.91 1231 0.62 2819
CD49c ITGA3 0.71 84 0.00 68 4393 0.31 50 86 920 0.00 138 0.00 103 0.00 47
CD49f ITGA6 0.90 371 0.00 257 266 0.00 151 89 39 0.95 717 0.95 304 0.00 243
CD50 ICAM3 0.00 158 0.00 192 2605 0.00 151 84 551 0.00 108 0.00 183 0.00 181
CD54 ICAM1 0.62 2675 0.00 1197 3508 0.00 1046 218 2452 0.00 924 0.00 2529 0.00 2415
CD56 NCAM1 0.00 38 0.00 30 76 1.00 36 152 1477 0.00 36 0.00 31 0.00 40
CD57 B3GAT1 0.00 30 0.51 53 404 0.00 27 23 47 0.03 33 0.03 34 0.67 144
CD58 CD58 0.33 560 0.03 343 292 0.06 230 175 61 0.01 280 0.01 509 0.01 530
CD59 CD59 0.38 2800 0.00 1681 1258 0.55 1247 1144 1858 0.66 2418 0.66 3658 0.00 2065
CD62L SELL 0.00 151 0.00 29 22 0.00 52 168 43 0.00 30 0.00 36 0.00 21
CD63 CD63 0.00 6719 0.81 4255 12035 0.00 4524 5360 17545 0.00 4872 0.00 7777 0.91 9750
CD64 FCGR1A 0.28 52 0.53 28 0.04 24 56 0.00 10 0.00 21 11
CD66f PSG1 0.00 9 0.00 10 33 0.00 9 75 34 0.00 35 0.00 10 0.10 10
CD70 CD70 0.00 124 0.00 94 0.00 70 303 0.00 75 0.00 111 89
CD73 NT5E 0.52 122 0.00 30 2162 0.00 103 669 5959 0.00 94 0.00 103 16
CD74 CD74 0.76 441 0.00 145 3731 0.00 161 209 1505 0.38 175 0.38 374 102
CD75s ST6GAL1 0.00 712 1.00 743 2095 0.01 185 145 80 0.04 490 0.04 976 0.50 640
CD84 CD84 0.00 29 0.00 21 112 0.00 19 82 208 0.00 20 0.00 24 0.00 17
CD88 C5AR1 0.00 150 0.00 33 687 0.00 59 174 276 0.00 52 0.00 118 0.00 27
CD90 THY1 0.71 255 0.00 105 498 0.15 372 277 962 0.00 83 0.00 183 0.00 64
CD91 LRP1 0.00 54 0.00 50 1687 0.05 94 69 3719 0.00 51 0.00 54 0.00 55
CD92 SLC44A1 0.00 220 0.02 115 1195 0.00 397 312 1060 0.30 227 0.30 243 0.00 149
CD94 KLRD1 0.00 33 0.01 25 22 0.02 26 42 29 0.00 24 0.00 24 0.00 22
CD95 FAS 0.02 230 0.18 133 482 0.00 536 260 561 0.43 378 0.43 121 0.03 289
CD98 SLC3A2 0.00 1561 0.37 1717 1456 0.00 904 142 503 0.02 1386 0.02 1694 0.14 2189
CD103 ITGAE 0.00 472 0.00 399 875 0.07 564 406 249 0.00 444 0.00 670 0.00 389
CD104 ITGB4 1.00 23 0.02 21 2665 0.00 19 58 1051 0.71 23 0.71 22 0.00 19
CD107a LAMP1 1.00 1775 1.00 2056 2248 0.36 2117 12017 654 0.23 2053 0.23 2158 0.19 2692
CD107b LAMP2 0.45 914 0.99 3101 26473 0.03 1219 1382 10028 0.49 1253 0.49 1077 0.67 1767
CD138 SDC1 0.00 83 0.01 144 1180 0.05 113 119 286 0.62 547 0.62 120 0.00 82
CD144 CDH5 1.00 917 0.00 221 39 0.00 224 77 40 0.00 527 0.00 1281 0.00 20
CD147 BSG 0.00 179 0.55 225 1056 0.05 302 151 524 0.45 251 0.45 232 0.37 351
CD153 TNFSF8 0.00 47 0.00 33 108 0.03 30 108 57 0.00 31 0.00 31 0.02 26
CD164 CD164 0.00 510 1.00 557 14331 0.05 435 2333 5228 0.01 453 0.01 525 0.03 633
CD166 ALCAM 0.00 795 0.16 1607 15170 0.00 376 1038 5373 0.03 815 0.03 493 0.21 2746
CD179a VPREB1 0.00 11 0.00 11 148 0.03 10 51 194 0.00 11 0.00 12 0.01 11
CD226 CD226 0.00 13 0.00 14 45 0.03 12 102 48 0.00 12 0.00 13 0.01 20
CD271 NGFR 0.00 22 0.00 23 145 0.00 22 36 45 0.81 24 0.81 23 0.00 23
Concordance: 55 64 36 46 39 25 63 64 68
Affymetrix mRNA data:  *Genes in the dataset with an average raw fluorescence signal <50 or > 50% of probesets measured absent 
    by Affymetrix GCOS Software analysis were considered to be undetected by the experiment
None Low Mid High
Expression level color scale: 0-50* 51-500 501-5000 >5000
Immunohistochemistry (IHC) data:  CD's in the dataset with scores of 0-0.250 were considered to be no more than background 
or no protein expression
None        Equivocal Intense
Expression level color scale:  0 - 0.25
0.251 - 
0.500 0.501 - 0.750 0.751 - 1.00
Agilent LCM array data:  Genes in the dataset with an average raw fluorescence signal <100 were considered absent 
None Low Mid High
Expression level color scale: 0-99 100-999 1000-9999 >9999BMC Genomics 2008, 9:246 http://www.biomedcentral.com/1471-2164/9/246
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ple, staining for CD26 (DPP4) in normal (A) and cancer
(B) prostate tissue shows clear luminal staining, which
corresponds with intense gene expression measured by
array in the luminal and cancer (05-179_CD26t) cell pop-
ulations. The greyscale gradient indicates robust multi-
array average (RMA) normalized Affymetrix signal inten-
sity. Signals of 10 or less are represented as white and sig-
nals greater than or equal to 10,000 are represented as
black. Higher Affymetrix signal (more black) indicates
higher levels of gene expression. CD26 expression deter-
mined by Agilent array in LCM luminal cells was also in
concordance (data shown in Figure 1). Immunostaining
with CD56 (NCAM1) showed clear stromal staining and
corresponding gene expression levels in both the MACS-
sorted and LCM stromal cell populations. Agilent array
analysis results for CD56 were 'absent' in luminal and
'present' in stromal cells as well (data shown in Figure 1).
Data type discordance is typified by CD44 (Figure 3).
Immunostaining with CD44 (G44-26, BD PharMingen,
San Diego, CA), was confined to the basal cells (A), how-
ever, measured gene expression was high in all cell types
(B). This antibody recognizes the epitope 1 of the stand-
ard variant of CD44 antigen. Affymetrix has 11 probe sets
Data-type concordance for CD26 and CD56 Figure 2
Data-type concordance for CD26 and CD56. CD immunoreactivity of prostate cells (immunoreaction product red-
brown; pale blue hematoxylin nuclear counterstain) and corresponding gene expression data (darker shading of the boxes indi-
cates higher mRNA levels). A. CD26 staining in normal prostate tissue was confined to luminal cells with a staining intensity of 
0.75, this correlated well with array data summary where a maximum gene expression level of 1240 was found for luminal cells. 
B. CD26 staining in prostate cancer was restricted to cancer cells with a staining intensity of 0.80, this correlates with array 
data where a maximum gene expression level of 868 was found for the cancer cells. C. CD56 staining in normal prostate tissue 
was confined to stromal cells with a staining intensity of 1.00, this agreed with array data where maximum gene expression 
level of 136 was found for stromal cells. Original magnification: 200×.
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for CD44, showing variable expression profiles, of which
only probe set 217523_at showed agreement with IHC
results. CD44 has a wide range of splice variants [16]
which may account for the discrepancy. Although micro-
array experiments detect mRNA, and it is mRNA that has
the direct relationship with protein, the methodology and
algorithms for Affymetrix data analysis are gene-based.
Gene level annotation fails to discriminate multiple
mRNAs transcribed from the same gene [17] such as is the
case with CD44 [18]. Affymetrix probesets for CD44 were
analyzed with Basic Local Alignment Search Tool
(BLAST). Probesets 204489_s_at, 204490_s_at,
209835_x_at, and 212063_at map directly to multiple
variants of CD44, whereas the other probesets map to
individual variants. It is likely that gene level annotation
compared to protein immunostaining will be less straight-
forward in cases such as CD44, where multiple protein
isoforms are generated from a single gene.
Further examples of data discordance for CD64
(FCGR1A), CD6 and CD24 expression are shown in Fig-
ure 4. For CD64, immunostaining identified the luminal
cell population, but measured gene expression was low or
absent for all cell types regardless of probeset (A). This was
also the case for CD6 (B). CD6 shows equivocal staining
of luminal cells. Examination of CD24 immunostaining
identifies the cancer cells, however measured gene expres-
sion was high across all cell types for some probe sets (i.e.
209771_x_at) and absent for others (i.e. 1560395_at).
Data-type discordance for CD44 Figure 3
Data-type discordance for CD44. CD44 immunoreactivity of prostate cells and corresponding gene expression data. A. 
CD44 staining in normal prostate was confined to basal cells with a staining intensity of 0.30, this contrasted with array data 
where gene expression levels were similar across all cell types. Original magnification: 200×. B. Examination of individual 
probesets showed that 217523_at was most similar to immunostaining results with a maximum gene expression level of 683 
for basal cells.
A
B
CD44 Intensity
0.30 
Intensity
801 BMC Genomics 2008, 9:246 http://www.biomedcentral.com/1471-2164/9/246
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Gene expression in LCM samples was also discordant
(data shown in Figure 1).
Correlation of immunolocalization with array data
Correlations between IHC staining intensity and gene
expression levels determined by Affymetrix array for
MACS-sorted cell populations are summarized in Table 1.
Statistical Pearson correlation ranged from -0.01 – 0.55
and Spearman Coefficients ranged from 0.00 – 0.51.
There was no positive overall correlation of immunolocal-
ization data with array data for endothelial, stromal or
progenitor cells, and moderate positive correlation for
luminal, basal and cancer. Scatter plots are shown in
Additional File 1. It has been suggested that under condi-
tions where expression differences are not dramatic, prob-
lems related to probe and probe set identity could lead to
significant errors [19]. Using updated probe set defini-
tions provided by Dai et al. [19], statistical correlations
ranged from 0.09 – 0.57 and Spearman Coefficients
ranged from 0.03 – 0.63 and are summarized in Table 2.
Updated probe set definitions increased correlation for all
cell types except for cancer cells (0.45 – 0.42). The greatest
Data-type discordance for CD64, CD6 and CD24 Figure 4
Data-type discordance for CD64, CD6 and CD24. CD immunoreactivity of prostate cells and corresponding gene 
expression data. A. CD64 staining of normal prostate was confined to luminal cells with a staining intensity of 0.53, contrasting 
with the array data where gene expression levels were absent across all cell types and for all probe sets. B. CD6 staining in 
prostate cancer was confined to cancer cells with a staining intensity of 0.35, in contrast with the array data where gene 
expression levels were absent across all cell types and for all probe sets with the exception of probe set 213958_at, where 
cancer, endothelial and luminal expression were present. C. CD24 staining in prostate cancer was confined to luminal cells 
with a staining intensity of 0.96, this contrasts with the array data where gene expression levels were present across all cell 
types and for all probesets with the exception of probeset 1560395_at, where expression levels were absent for all cell types. 
Original magnification: 200×.
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improvement was a 2-fold increase for progenitor (Spear-
man 0.22 – 0.41). Scatter plots are shown in Additional
File 2. In summary, for either probe set definition, there
was no positive correlation of immunolocalization with
transcriptome data for endothelial or stromal cells, and
moderate positive correlation for luminal, basal, and can-
cer. Updated probe set definitions increased correlation
from none to moderate positive correlation for progenitor
cells.
LCM confirmation
Correlations between IHC staining intensity and gene
expression determined by Affymetrix and Agilent array for
LCM cells are summarized in Table 3. Statistical Pearson
correlation ranged from 0.26 – 0.57 and Spearman Coef-
ficients ranged from 0.25 – 0.43. There was no positive
correlation of immunolocalization data with array data
for LCM stromal cells assayed by either Agilent or Affyme-
trix. Pearson correlation for LCM luminal cells was 0.57
and Spearman coefficient was 0.43, which were the same
values as that for MACS-sorted luminal cells using
updated probe set definitions. Pearson correlation
between LCM stromal cell data and MACS-sorted stromal
cell data assayed by Affymetrix array was 0.68, Spearman
coefficient was 0.78. Pearson correlation between LCM
stromal cell data analyzed by Agilent array and Affymetrix
MACS-sorted stromal cell data was 0.65, Spearman coeffi-
cient was 0.55. Pearson correlation between LCM stromal
cell data analyzed by Agilent array and Affymetrix LCM
stromal cell data was 0.33, Spearman coefficient was 0.59.
Scatter plots are shown in Additional File 3.
Discussion
In this study, we analyzed the gene and protein expression
of 58 informative CD antibodies in prostate tissue to
determine the degree of concordance between immuno-
histochemical assessments of protein abundance and
microarray-based measures of transcript levels. Based on
previous characterization of prostate cancer by CD pheno-
type [13,20], we were interested in the correlation with
corresponding cell type-specific transcriptome data and
the relationship between MACS-sorted cell and laser cap-
ture microdissected populations. The CD antibodies used
for comparison were selected based on their previously
determined cell type specificity in prostate tissue [20]. For
this study, there was good agreement between CD pheno-
type characterized by immunostaining and gene expres-
sion level based on 'absent' or 'present' call. Quantitative
comparison of expression levels mirrored these results
with correlation being lowest for stromal cells and highest
for luminal cells and cancer cells. There was moderate
positive correlation between measured gene expression
level and immunostaining intensity for luminal, basal
and cancer. There was moderate positive correlation for
progenitor cells using updated probe set definitions.
Previous work in our lab has indicated that Affymetrix
'present' calls are approximately 90% accurate, however,
Table 1: Correlation between immunostaining intensity and mRNA level for each prostate cell type
Median Mean
Cell type Spearman coefficient Pearson Spearman coefficient Pearson
CD31 Endothelial 0.25 0.28 0.26 0.28
CD26 Luminal 0.46 0.47 0.51 0.55
CD49a Stromal -0.00 -0.01 0.06 0.07
CD104 Basal 0.35 0.31 0.42 0.34
ABCG2 Progenitor 0.22 0.17 0.34 0.23
CD26 Cancer 0.45 0.49 0.49 0.50
Table 2: Correlation between immunostaining intensity and mRNA level using updated probeset definitions for each prostate cell 
type
Median Mean
Cell type Spearman coefficient Pearson Spearman coefficient Pearson
CD31 Endothelial 0.43 0.57 0.28 0.27
CD26 Luminal 0.57 0.61 0.57 0.63
CD49a Stromal 0.09 0.03 0.09 0.03
CD104 Basal 0.49 0.45 0.49 0.45
ABCG2 Progenitor 0.41 0.33 0.41 0.34
CD26 Cancer 0.42 0.49 0.42 0.49BMC Genomics 2008, 9:246 http://www.biomedcentral.com/1471-2164/9/246
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'absent' calls are only 40% accurate [21]. Most often genes
classified by array analysis as absent were, in fact,
expressed when measured by more sensitive RT-PCR
methods, but were of very low abundance. With respect to
characterizing CD expression by immunostaining, there
were few cases where CD expression was scored by immu-
nostaining and not by gene arrays. In fact, it was more
likely that CD genes classified as present by array were not
immunostained by that CD antibody. There are several
possible explanations for these discrepancies. Biological
reasons for poor correlation include post-transcriptional
and post-translational modifications, as well as the possi-
bility that proteins have very different half-lives [22,23].
Recent analyses indicate that protein concentrations cor-
relate with the corresponding mRNA levels by only 20 –
40%, and that mRNA abundances are only a weak surro-
gate for corresponding protein concentration [24,25]. Fur-
ther complicating matters is the potential for errors and
noise in protein and mRNA experiments. Although we
have previously documented the advantages of MACS-
sorted cell over whole tissue transcriptomes [13] gene
expression may be affected by collagenase tissue digestion
and cell isolation processes. To examine this possibility
we compared array results from MACS-sorted cells with
LCM cells. Results for luminal cells were virtually the same
for LCM and MACS-sorted cells, however for stromal cells,
correlation increased about 3-fold (from 0.08 in MACS-
sorted cells to 0.26 in LCM indicating that for stromal cells
the non-specific detection is due to low levels of contam-
inating cells in the MACS-sort cells. Gene expression anal-
ysis is much more sensitive than immunohistochemistry,
but it may also be that genes expressed are at levels not
high enough for translated protein expression. Satisfac-
tory immunostaining of surface membrane antigens
requires preservation of protein tertiary structure in the
region of the relevant epitopes [26] and it may be that
some of these CD antibodies are less immunoreactive
than others. Additionally, some mRNAs may cross-
hybridize probes in the array that are designed to detect
another mRNA, or probes that are designed to detect the
mRNA of a particular gene may be relying on genomic
expressed sequence tag (EST) information that is incor-
rectly associated with that gene. Clearly there are difficul-
ties associated with some antigens such as those we found
in CD44, CD64 (FCGR1A), CD6 and CD24 where probe
set variability indicates that IHC is a better method for
analysis at this time. The use of updated probe set defini-
tions slightly increased correlations for all cell types indi-
cating that inaccurate probe sets may account for some of
the disparities found between the two techniques in this
study. For studies involving the prostate, suggested targets
for CD profiling using the combination of DNA array and
IHC technologies are listed in Table 4.
Many cross-platform studies have been conducted on
DNA microarrays. These previous studies have discovered
several factors that effect data comparison across different
microarray platforms. In addition to our findings,
updated annotation through RefSeq or UniGene data-
bases has repeatedly been shown to increase cross-plat-
form content and consistency [27-31]. Biological
variability, and inter-laboratory variation have also been
previously implicated as sources of cross-platform data
Table 3: Correlation between immunostaining intensity and 
mRNA level for LCM samples.
Mean
Cell type Spearman coefficient Pearson
CD26 Luminal 0.43 0.57
Agilent
CD49a Stromal 0.26 0.26
Affymetrix
CD49a Stromal 0.25 0.28
Agilent
Table 4: Suggested CD profiling targets with good agreement between data types for prostate characterizations.
Cell type CD antigens 'present' CD antigens 'absent'
CD31 Endothelial 31, 49f, 54, 58, 59, 73, 74, 90, 107a, 107b, 144 1a, 6, 10, 30, 32, 41, 43, 56, 66f, 70, 75s, 84, 91, 94, 179a, 226, 
271
CD26 Luminal 9, 10, 13, 26, 38, 63, 75s, 98, 107a, 107b, 147, 164 1a, 6, 30, 32, 41, 43, 49c, 50, 56, 66f, 70, 74, 84, 88, 91, 94, 104, 
153, 179a, 226, 271
CD49a Stromal 29, 47, 49a, 56, 59 1a, 6, 26, 30, 32, 41, 43, 50, 64, 66f, 70, 75s, 84, 91, 94, 104, 153, 
179a, 271
CD104 Basal 9, 44, 47, 49b, 49f, 59, 74, 92, 95, 104, 107b, 138, 147, 271 1a, 6, 30, 32, 41, 43, 49c, 50, 56, 64, 66f, 70, 75s, 84, 91, 94, 153, 
179a, 226
ABCG2 Progenitor 9, 44, 47, 49b, 49f, 59, 74, 92, 95, 138, 147 1a, 6, 30, 10, 13, 26, 30, 32, 41, 43, 49c, 50, 56, 64, 66f, 70, 84, 
91, 94, 153, 179a, 226
CD26 Cancer 9, 24, 26, 29, 38, 40, 46, 49b, 63, 75s, 147 10, 13, 30, 32, 41, 43, 49c, 50, 56, 62L, 66f, 84, 88, 90, 91, 94, 
104, 144, 153, 179a, 226, 271
'Present' denotes the list of CD antigens expressed by the specific cell type and detected as by both array and IHC. 'Absent' cites the list of CD 
antigens undetected by both array and IHC.BMC Genomics 2008, 9:246 http://www.biomedcentral.com/1471-2164/9/246
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discrepancies [32-34]. For this study, although conducted
by two different laboratories, the correlation between the
two platform types (Affymetrix and Agilent) was only dif-
ferent for prostate stromal cells. Therefore, it is probable
that these discrepancies were due to varying sampling
methods (e.g. MACS-sorting of digested tissue vs. LCM of
frozen tissue sections). Additionally, discrepancy could be
due to the differing tissue histology of the prostate and
therefore possible differing purity for stromal vs. luminal
cell types. The prostate stroma is fairly heterogenous, con-
sisting of smooth muscle cells and fibroblasts, with
embedded blood vasculature, peripheral nerves and gan-
glia, and tissue infiltrating white blood cells; whereas the
prostate luminal layer contains luminal secretory cells and
rare neuroendocrine cells.
Conclusion
In summary, CD molecules can be used to isolate cell
populations from prostate tissue. These cell populations
retain to a high degree their CD phenotype as determined
by immunostaining in intact tissue. Observed discrepan-
cies were mostly in expression levels detected by microar-
ray and not immunohistochemistry; these differences are
possibly due in part to varying sampling methods, prob-
lems related to probe and probe set identity as well as
actual biological differences. It is hoped that continued
improvements in cell sorting techniques and probe set
development could further elucidate the relationship
between mRNA levels and corresponding protein expres-
sion. In addition to comparison of immunohistochemis-
try and microarray data, there is further need for cross-
comparison of results utilizing techniques such as in situ
hybridization, western blotting and high throughput pro-
teome analysis. Future studies analyzing mRNA and pro-
tein correlation will be required to determine the
potential bias of various experimental methodologies as
well as how mRNA expression differences are related to
protein expression.
Methods
Prostate tissue
The methods of tissue collection, immunostaining and
expression data collection and analysis used in this study
have been published previously [13,20,35]. Briefly, tissue
samples for IHC and Affymetrix array analysis consisted of
both cancer-enriched and cancer-free samples obtained
from 55 radical prostatectomies. Upon receipt of prostate-
ctomy specimens, 3-mm thick transverse sections were
made of the prostate after inking the exterior surface (the
surgical margin). The same approach was used for both
cancer-free and cancer-enriched (where at least 85% of the
cells in the corresponding frozen section were cancer
cells) samples. Between 4 and 6 blocks of tissue from the
posterior aspect (the peripheral zone) of each prostate
were frozen. Sections from the frozen blocks of tissue pro-
vided a histological template for characterizing the cell
composition of the adjacent non-frozen tissue blocks.
Cancer-free samples, weighing between 2 and 10 g, were
harvested primarily from the anterior aspect of the pros-
tate (transition zone) as described [12,13,35]. Cancer-
enriched samples, weighing at least 100 mg, were dis-
sected from the opposing aspect of the non-fixed section
adjacent to the block of tissue that had been frozen. Tissue
specimens for cell sorting were digested by collagenase
[36,37].
As an external control, IHC and array data from MACS-
sorted cells were compared to LCM cells from prostate
stromal and luminal cells analyzed by hybridization to
long-oligonucleotide microarrays (Agilent Corporation).
Additionally, LCM stromal cells were analyzed by Affyme-
trix array to control for potential platform variation. Tis-
sue specimens for LCM were obtained from prostate
needle biopsies from 14 men identified from a biospeci-
men repository with no evidence of cancer as well as a sec-
ond or third set of biopsies that also showed no evidence
of carcinoma. Each biopsy specimen was immediately
embedded in OCT and flash frozen in isopentane
immersed in liquid nitrogen. All protocols for tissue
acquisition and processing were under approval by the
University of Washington Institutional Review Board fol-
lowing a standard protocol.
Immunohistochemistry
Blocks of unfixed prostate tissue were harvested at surgery.
Serial 5-μm sections were prepared from randomly
selected frozen blocks, fixed in cold acetone, and proc-
essed for immunohistochemistry. We used frozen sections
since a majority of the anti-CD antibodies we used do not
immunoreact with antigens in formalin-fixed, paraffin-
embedded tissue. Immunohistochemistry was performed
as described previously [20]. The primary antibodies used
were mouse monoclonal CD antibodies (BD-PharMin-
gen, San Diego, CA) diluted to 8 ng/μl or less. Antigen was
localized using biotinylated anti-mouse IgG or IgM (Vec-
tor Labs, Burlingame, CA) as the secondary antibody and
diaminobenzidine tetrahydrochloride as the chromogen.
The sections were counterstained with hematoxylin.
The percentage of cells of a specific histological phenotype
that expressed the antigen was estimated in five randomly
selected fields at a final magnification of 40× (ocular 10×;
objective 4×). Staining intensity was evaluated by two
parameters (staining intensity and percentage of cells
exhibiting each level of intensity). Intensity of reaction
product was based on a 3-point scale – none, faint/equiv-
ocal and intense. These categories of staining intensity
were defined as follows. Intense: immunoreaction deposit
is distinctly more optically dense than background and
than tissue that does not express the antigen. Equivocal:BMC Genomics 2008, 9:246 http://www.biomedcentral.com/1471-2164/9/246
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immunoreaction deposit is either similar enough in opti-
cal density to the background and/or to tissue that does
not express the antigen, or is so focal, i.e. < 5% of cells,
that there is reasonable uncertainty regarding whether the
cells express the antigen. None: there is either no immuno-
reaction deposit or reaction product is no more optically
dense than background.
A single value A was calculated for each immunostain by
cell type using the following formula:
WF = weighting factor, usually 0.2
The value of the weighting factor can be changed on our
web site by independent observers of the images. We did
this since we thought that observers of the images should
be able to alter the value assigned to the weighting factor
based on whether they thought that faint/equivocal
immunostained cells either did or did not truly represent
immunolocalization of each respective CD antigen. For
the present study we used a weighting factor of 0.2.
An average score for each cell type for each CD antigen
was calculated using the following equation:
where:
n = number of immunostains for each CD by cell type
A = staining value for each immunostain by cell type
Average scores in the range of 0.751 to 1.0 were catego-
rized as intense, 0.251 to 0.750 as equivocal or 0 to 0.250
as none. Immunostained sections were imaged with an
Olympus BX41 microscope (Olympus, Melville, NY)
equipped with a MicroFire digital camera (Optronics,
Goleta, CA). Composite images were constructed with
Photoshop CS (Adobe Systems, San Jose, CA) and are
publicly available online [38].
Affymetrix gene expression profiling of MACS-sorted cell 
populations and laser captured stromal cells
Transcriptomes of the following prostate cell types have
been previously determined: CD104+  basal epithelial
cells, CD26+  luminal epithelial cells, CD49a+  stromal
fibromuscular cells, and CD31+ endothelial cells [13],
ABCG2+ stem cells [39] and CD26+ cancer cells [in prepa-
ration]. The CD molecules cited above were the ones used
for sorting each specific cell type for gene expression pro-
filing. The expression of genes documented in the litera-
ture as cell-type specific was compared to Affymetrix
datasets; analyses showed that the transcriptomes were
representative of their respective cell type (p < 0.05) [13].
Five separate biological replicates of each MACS-sorted
cell populations (except the CD26+ cancer cells which
comprised of one biological sample) and three separate
biological replicates of laser captured stromal cells were
assayed to produce a dataset using the Human Genome
U133 Plus 2.0 GeneChips (Affymetrix, Santa Clara, CA).
The U-133 Plus 2.0 array contains probesets representing
54,675 genes, splice variants, and ESTs. The GeneChips
were prepared, hybridized, and scanned according to the
protocols provided by Affymetrix. Briefly, 200 ng of RNA
was reverse transcribed with poly (dT) primer containing
a T7 promoter, and the cDNA was made double-stranded.
In vitro transcription was performed to produce unla-
beled cRNA. Next, first-strand cDNA was produced with
random primer. cDNA was made double-stranded with
poly (dT) primer/T7 promoter. Finally, in vitro transcrip-
tion was performed with biotinylated ribonucleotides.
The biotin-labeled cRNA was hybridized to the Gene-
Chips. The chips were washed and stained with streptavi-
din-PE using an Affymetrix FS-450 fluidics station. Data
was collected with an Affymetrix GeneChip Scanner 3000.
LCM and RNA isolation of luminal and stromal cells for 
Agilent array analysis
Approximately two thousand luminal epithelial or stro-
mal cells from histologically benign glands were captured
using the Veritas Microdissection System (Molecular
Devices Corporation, Sunnyvale, CA) as previously
described [40]. Frozen sections (8 μm) were cut from tis-
sue embedded in OCT (Miles, Inc. Diagonostic Division,
Elkhart, IN) and fixed in cold 95% ethanol. After brief (5–
10 seconds) staining with hematoxylin using the His-
toGene staining solution (Arcturus Engineering, Moun-
tain View, CA), the sections were dehydrated in 100%
ethanol, followed by sequential ethanol-xylene solutions.
Three stromal cell samples and 14 luminal cell samples
were captured. Digital photographs were taken of tissue
sections before, during, and after LCM and assessed inde-
pendently by two investigators to confirm that the laser-
captured cells were stromal and luminal cells, respec-
tively.
Captured individual specimens were lysed and RNA was
isolated using Arcturus PicoPure RNA Isolation. Samples
were treated with RNase-free DNase (Qiagen, Inc., Valen-
cia, CA). This RNA was converted to a cDNA library and
amplified using the TransPlex WTA (Rubicon Genomics,
Ann Arbor, MI) using Titanium Taq polymerase (Clon-
tech Laboratories, Inc., Mountain View, CA) in the pres-
ence of amino-allyl deoxyuridine triphosphate (dUTP) for
postamplification labeling. Real-time PCR amplifications
were terminated at plateau phase, as measured by fluores-
A =
0(% no stain) WF(% faint/equivocal stain) 1(% convincing ++    stain)
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cence incorporation, to preserve maximum representa-
tion. Concentration and purity was determined using the
ND-1000 spectrophotometer (Nanodrop Technologies,
Wilmington, DE). To provide a reference standard RNA
for use on 2-color microarrays, we isolated total RNA from
LNCaP, DU145, PC3, and CWR22 cell lines (American
Type Culture Collection, Manassas, VA) growing at log
phase in dye-free RPMI-1640 medium supplemented with
10% fetal bovine serum (FBS; Life Technologies, Rock-
ville, MD). RNA was purified using Trizol (Life Technolo-
gies). The RNA was then further purified by Qiagen
RNeasy maxi and treated with Qiagen RNase-free DNase.
This total RNA was then amplified using the TransPlex
WTA similar to the experimental samples.
Gene expression profiling on Agilent microarrays
Two μg of WTA-amplified amino-allyl cDNA from each of
14 luminal and 3 stromal samples were labeled with Cy3
fluorescent dye (cell line reference cDNA was labeled with
Cy5) as described previously [40], and hybridized to Agi-
lent 44 K whole human genome expression oligonucle-
otide microarray slides (Agilent Technologies, Inc., Santa
Clara, CA) following the manufacturer's suggested proto-
cols. Fluorescence array images were collected for both
Cy3 and Cy5 using an Agilent fluorescent scanner, and
Feature Extraction software (Agilent Technologies, Santa
Clara, CA, USA) was used to grid, extract image intensities,
and normalize data. Spots of poor quality, as determined
by the software, were removed from further analysis. Data
from the 14 luminal or 3 stromal samples were combined
and the average signal values were used for comparative
analyses. For genes with multiple probes on the array, the
data from the probe with the highest sequence specificity
was chosen.
Data comparison and statistical analysis
Immunohistochemistry data was compared to Affymetrix
array data for the following prostate cell types: MACS-
sorted basal cells, luminal cells, stromal fibromuscular
cells, endothelial cells, stem cells and cancer cells from a
primary tumor of Gleason 3+3 = 6. Additionally IHC data
was compared to Affymetrix array data for LCM stromal
and Agilent array data for LCM stromal and epithelial
cells. Data was analyzed for concordance and correlation
of expression levels. Data concordance was defined as
agreement between data types based on 'present' or
'absent' calls, i.e., if both techniques detected a gene, they
were considered to be in agreement. Genes in the Affyme-
trix array dataset with an average raw fluorescence signal <
50 were considered to be undetected by the experiment
and were classified as 'absent' by GCOS version 1.0 soft-
ware (Affymetrix) [13]. Genes were also classified as unde-
tected if the majority (> 50%) of individual probe sets
were classified as 'absent'. All other hybridization patterns
were classified as 'present'. Genes with signal 51–500 were
considered to have 'low' expression, those with signal
501–5000 were considered to have 'medium' expression,
and those with signal > 5000 were considered to have
'high' expression. Genes in the Agilent array dataset with
an average raw fluorescence signal < 100 were considered
to be 'absent', those with signal 100–999 were considered
to have 'low' expression, those with signal 1000–9999
were considered to have 'medium' expression, and those
with signal > 9999 were considered to have 'high' expres-
sion. Immunohistochemistry data having a staining level
of intense  (score range 0.751 – 1.0) or equivocal (score
range 0.251 – 0.750) were classified as in agreement with
genes classified as 'present'. Immunostaining results of
none (score range 0 – 0.250) were considered equivalent
to 'absent'.
The correlation between mRNA expression levels and
immunostaining intensity for each CD antibody was
described by Pearson product-moment and Spearman
nonparametric correlation measures and tests. Correla-
tions were calculated for mean and median values.
Median was included as a more robust measurement in
the presence of outlier or skewed values especially for the
array data. Individual Affymetrix probes within a probe
set were originally designated to hybridize with the same
unique mRNA transcript. However, increasing knowledge
of genomic sequences has shown that a substantial
number of the manufacturer's original probe groupings
and mappings are inaccurate and must be corrected [41].
To address the possibility that disparity in expression level
was due to probe set definition, correlation was addition-
ally determined using updated custom CDF definitions
[19]. Dai et al., have reorganized probe set definitions
based on the latest genome and transcriptome informa-
tion [17]. These updated definitions based on Version 8
Entrez Gene mappings were downloaded and used in
addition to the Affymetrix probe set definitions. To con-
trol for possible gene expression changes induced by the
cell sorting process, LCM data for stromal cells were also
compared for correlation. Additionally, LCM data for
luminal and stromal cells assayed by Agilent array analysis
was also used for correlation calculations. Correlations
were calculated using both original and updated probe set
definitions and were categorized as follows: no positive
correlation (0.00 to 0.30), moderate positive correlation
(0.31 to 0.79), and strong positive correlation (0.80 to
0.99).
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